Antioxidant effects of insulin-like growth factor-I (IGF-I) in rats with advanced liver cirrhosis

BMC Gastroenterology

Volumn 5, Issue , 2005, Pages

  García Fernández, María ^a,b   Castilla Cortázar, Inma ^a,b,c   Díaz Sanchez, Matías ^a   Navarro, Iñigo ^a   Puche, Juan Enrique ^b,c   Castilla, Alberto ^d   Díaz Casares, Amelia ^b,c   Clavijo, Encarna ^b   González Barón, Salvador ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c UNIVERSIDAD SAN PABLO CEU   (Spain)

^d HOSPITAL SIERRALLANA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; COPPER; DNA; FERRITIN; FREE RADICAL; HYDROXYL RADICAL; INDUCIBLE NITRIC OXIDE SYNTHASE; IRON; LIPID; MYELOPEROXIDASE; NITRIC OXIDE; PHENOBARBITAL; RECOMBINANT SOMATOMEDIN C; TRANSFERRIN; ANTIOXIDANT; MALONALDEHYDE; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASCITES; ATOMIC ABSORPTION SPECTROMETRY; CONTROLLED STUDY; DNA DAMAGE; DRUG DOSE REGIMEN; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROGENESIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID MEMBRANE; LIPID PEROXIDATION; LIVER CIRRHOSIS; LIVER LEVEL; LIVER PROTECTION; MALE; METABOLIC PARAMETERS; NONHUMAN; OXIDATIVE STRESS; PARALLEL DESIGN; PROTEIN EXPRESSION; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; TISSUE INJURY; TURBIDIMETRY; ANIMAL; EXPERIMENTAL LIVER CIRRHOSIS; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; COPPER; FERRITINS; INSULIN-LIKE GROWTH FACTOR I; IRON; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MALONDIALDEHYDE; OXIDATION-REDUCTION; RATS; RATS, WISTAR; TRANSFERRIN;

EID: 25444524336     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-5-7     Document Type: Article

References (58)

1. Sara VR, Hall K: Insulin-like growth factor-I and their binding proteins. Physiol Rew 1990, 70:591-613.
2. Caufriez A, Reding P, Urbain D, Goldstein J, Copinschi G: Insulin-like growth factor-I: a good indicator of functional hepatocelular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991, 14:317-321.
3. Hattori N, Kurahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M, Saiki Y, Imura H: Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis. Metabolism 1992, 41:377-381.
4. Möller S, Becker U, Juul A, Skakkebæk NE, Christensen E, Group E: Prognostic Value of Insulin-like Growth Factor-I ans its Binding Proteins in patients with alcohol-induced Liver disease. Hepatology 1996, 23:1073-1078.
5. Schimpff RM, Lebrec D, Donadieu M: Somatomedin production in normal adults and cirrhotic patients. Acta Endocrinol 1977, 86:355-362.
6. Picardi A, De Oliveira AC, Muguerza B, Tosar A, Quiroga J, Castilla-Cortazar I, Santidrian S, Prieto J: Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol 1997, 26:191-202.
7. Castilla-Cortázar I, Prieto J, Urdaneta E, Pascual M, Nuñez M, Zudaire E, García M, Quiroga J, Santidrián S: Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulinlike growth factor I. Gastroenterology 1997, 113:1180-1187.
8. Castilla-Cortázar I, Picardi A, Ainzua J, Urdaneta E, Tosar A, García M, Quiroga J, Prieto J: Effect of insulin-like growth factor 1 on in vivo intestinal absorption in cirrhotic rats. Am J Physiol 1999, 276:G637-G642.
9. Castilla-Cortazar I, Garcia M, Quiroga J, Diez N, Diez-Caballero F, Calvo A, Diaz M, Prieto J: Insulin-like growth factor-1 reverts testicular atrophy in rats with advanced cirrhosis. Hepatology 2000, 31:592-600.
10. Pascual M, Castilla-Cortazar I, Urdaneta E, Quiroga J, Garcia M, Picardi A, Prieto J: Altered intestinal transport of amino acids in cirrhotic rats: the effect of insulin-like growth factor-1. Am J Physiol Gastrointest Liver Physiol 2000, 279:319-324.
11. Cemborain A, Castilla-Cortázar I, García M, Quiroga J, Muguerza B, Picardi A, Santidrián S, Prieto J: Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-1 treatment. J Hepatol 1998, 28:122-131.
12. Cemborain A, Castilla-Cortazar I, Garcia M, Muguerza B, Delgado G, Diaz-Sanchez M, Picardi A: Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem 2000, 56:91-99.
13. Castilla-Cortazar I, Aliaga-Montilla MA, Salvador J, Garcia M, Delgado G, Gonzalez-Baron S, Quiroga J, Prieto J: Insulin-like growth factor-1 restores the reduced somatostatinergic tone controlling growth hormone secretion in cirrhotic rats. Liver 2001, 21:405-409.
14. Castilla-Cortázar I, García M, Muguerza B, pérez R, Quiroga J, Santidrián S, Prieto J: Hepatoprotective Effects of Insulin-like Growth Factor-1 in Rats with Carbon-Tetrachloride-Induced Cirrhosis. Gastroenterology 1997, 113:1682-1691.
15. Mirpuri E, Garcia-Trevijano ER, Castilla-Cortazar I, Berasain C, Quiroga J, Rodriguez-Ortigosa C, Mato JM, Prieto J, Avila MA: Altered liver gene expression in CC14-cirrhotic rats is partially normalized by insulin-like growth factor-1. Int J Biochem Cell Biol 2002, 34:242-252.
16. Muguerza B, Castilla-Cortazar I, Garcia M, Quiroga J, Santidrian S, Prieto J: Antifibrogenic effect in vivo of low doses of insulin-like growth factor-1 in cirrhotic rats. Biochim Biophys Acta 2001, 1536:185-195.
17. Bacon BR, Britton RS: Hepatic injury in chronic iron overload. Role of lipid peroxidation. Chem Biol Interactions 1989, 70:183-226.
18. Sokol RJ: Antioxidant Defenses in Metal-Induced Liver Damage. Semin Liver Dis 1996, 16:39-46.
19. Stohs SJ, Bagchi D: Oxidative mechanisms in the toxicity of metal ions. Free Radical Biol Med 1995, 18:321-336.
20. Arora AS, Gores GJ: The role of metals in ischemia/reperfusion injury of the liver. Semin Liver Dis 1996, 16:31-38.
21. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB: Iron in Liver Diseases other than Hemochromatosis. Semin Liver Dis 1996, 16:65-82.
22. Hubert N, Lescoat G, Sciot R, Moirand R, Jego P, Leroyer P, Brissot P: Regulation of ferritin and transferrin receptor expression by iron in human hepatocyte cultures. J Hepatol 1993, 18:301-312.
23. Rosen GM, Pou S, Ramos AL, Cohen MS, Britigan BE: Free radicals and phagocytes cells. Faseb J 1995, 9:200-209.
24. National Academy of Sciences: The Guiding principles for research involving animals. Washington, DC: National Institutes of Health; 1991.
25. Farinati F, Cardin R, De Maria N, Libera G, Marafin C, Lecis E, Burra P, Florean A, Cecchetto A, Naccarato R: Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995, 22:449-456.
26. Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y: Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997, 41:115-120.
27. Shu S, Ju G, Fan LZ: The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett 1988, 85:169-171.
28. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
29. Gutteridge JMC: Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995, 41:1819-1828.
30. Yu BP: Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994, 74:139-162.
31. Rosser BG, Gores GJ: Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology 1995, 108:252-275.
32. Bacon BR, Britton RS: The pathology of hepatic iron overload: a free radical - mediated process? Hepatology 1990, 11:127-37.
33. Trinder D, Macey DJ, Olynyk JK: The new iron age. Int J Mol Med 2000, 6:607-612.
34. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE: Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996, 25:633-638.
35. Haque S, Chandra B, Gerber MA, Lok AS: Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum Pathol 1996, 27:1277-1281.
36. Cairo G, Tacchini L, Pogliaghi G, Anzon E, Tomasi A, Bernelli-Zazzera A: Induction of ferritin synthesis by oxidative stress. Transcriptional and post-transcriptional regulation by expansion of the "free" iron pool. J Biol Chem 1995, 270:700-703.
37. Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. New York: Oxford University Press; 1989.
38. Dix DJ, Lin PN, Mckenzie AR, Walden WE, Theil EC: The influence of the base-paired flanking region on structure and function of the ferritin mRNA Iron Regulatory Element. J Mol Biol 1993, 231:230-240.
39. Schalinske K, Chen OS, Eisenstein RS: Iron Differentially translation of mitochondrial aconitase and ferritin mRNAs in mammalian cells. J Biol Chem 1998, 273:3740-3746.
40. Dhumeaux D, Hezode C: [Iron overload and liver diseases (except for hemochromatosis and dysmetabolic hepatosiderosis]. Bull Acad Natl Med 2000, 184:349-354.
41. Cairo G, Tacchini L, Pietrangelo A: Lack of coordinate control of ferritin and transferrin receptor expression during rat liver regeneration. Hepatology 1998, 28:173-178.
42. Sunstrom NA, Gay RD, Wong DC, Kitchen NA, Deboer L, Gray PP: Insulin-like growth factor-1 and transferrin mediate growth and survival of Chinese hamster ovary cells. Biotechnol Prog 2000, 16:698-702.
43. Merchav S: The haematopoietic effects of growth hormone and insulin-like growth factor-1. J Pediatr Endocrinol Metab 1998, 11:677-685.
44. Panzenbock B, Bartunek P, Mapara MY, Zenke M: Growth and differentiation of human stem cell factor/erythropoietindependent erythroid progenitor cells in vitro. Blood 1998, 92:3658-3668.
45. Sternlieb I: Copper and Zinc. In The Liver Biology and Pathobiology Edited by: Arias IM, Boyer JL, Fausto N. New York: Raven Press; 1994:585-596.
46. Brown KE, Brunt EM, Heinecke JW: Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol 2001, 159:2081-2088.
47. Wang H, Chen XP, Qiu FZ: Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats. Hepatobiliary Pancreat Dis Int 2003, 2(3):391-396.
48. Bhimani EK, Serracino-Inglott F, Sarela AI, Batten JJ, Mathie RT: Hepatic and mesenteric nitric oxide synthase expression in a rat model of CCl(4)-induced cirrhosis. J Surg Res 2003, 113(1):172-178.
49. Mohammed NA, Abd El-Aleem S, Appleton I, Maklouf MM, Said M, McMahon RF: Expression of nitric oxide synthase isoforms in human liver cirrhosis. J Pathol 2003, 200(5):647-655.
50. Helmy A, Newby DE, Jalan R, Hayes PC, Webb DJ: Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003, 52(3):410-415.
51. Yang W, Benjamin IS, Moore K, Portmann B, Alexander B: The action of nitric oxide on hepatic haemodynamics during secondary biliary cirrhosis in the rat. Eur J Pharmacol 2003, 461(1):41-48.
52. Koruk M, Aksoy H, Akcay F, Onuk MD: Antioxidant capacity and nitric oxide in patients with hepatic cirrhosis. Ann Clin Lab Sci 2002, 32(3):252-256.
53. Arkenau HT, Stichtenoth DO, Frolich JC, Manns MP, Boker KH: Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol 2002, 40(11):907-913.
54. Gonzalez-Abraldes J, Garcia-Pagan JC, Bosch J: Nitric oxide and portal hypertension. Metab Brain Dis 2002, 17((4)):311-324.
55. Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ: A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003, 39(6):940-946.
56. Van De Casteele M, Van Pelt JF, Nevens F, Fevery J, Reichen J: Low NO bioavailability in CCl 4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: A comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol 2003, 10(2(1)):2.
57. Bellis L, Berzigotti A, Abraldes JG, Moitinho E, Garcia-Pagan JC, Bosch J, Rodes J: Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003, 37(2):378-384.
58. Rockey DC, Chung JJ: Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998, 114(2):344-51.